Anterogen Competitors and Similar CompaniesClear all
Anterogen's competitors and similar companies include CEL-SCI, Topas Therapeutics, ONCOtherapeutics and Saniona.
 Anterogen Anterogen is a biotech company that researches and develops cell therapy products and drugs using adult stem cells. |  CEL-SCI CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases. |  Topas Therapeutics Topas Therapeutics is a development stage company that intends to build neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. |  ONCOtherapeutics ONCOtherapeutics is a contract research organization that runs multiple clinical trials. |  Saniona Saniona, a research and development company, engages in the development of drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. | |
Founding Date | Founding Date 2000 | Founding Date 1983 | Founding Date 2013 | Founding Date 2005 | Founding Date 2011 |
Type | Type Public | Type Public | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations KR HQ | Locations Vienna, US HQ | Locations Hamburg, DE HQ Bremen, DE | Locations West Hollywood, US HQ | Locations Ballerup, DK HQ Glostrup, DK Waltham, US |
Employees | Employees N/A | Employees N/A | Employees N/A | Employees 13 | Employees 22 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 58.7 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 42.9 m |
Financial | |||||
Revenue (est.) | Revenue (est.) ₩7.5b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) kr434.4m (FY, 2025) |
Cost of goods | Cost of goods ₩4.6b (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods kr5.4m (FY, 2025) |
Gross profit | Gross profit ₩3b (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit kr429m (FY, 2025) |
Net income | Net income (₩1.4b) (FY, 2025) | Net income ($25.4m) (FY, 2025) | Net income N/A | Net income N/A | Net income kr284.7m (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
CEL-SCI
HQ
Vienna, US
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
View companyTopas Therapeutics
HQ
Hamburg, DE
Topas Therapeutics is a development stage company that intends to build neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis.
View companyONCOtherapeutics
HQ
West Hollywood, US
Employees
13
ONCOtherapeutics is a contract research organization that runs multiple clinical trials.
View companySaniona
HQ
Ballerup, DK
Employees
22
Saniona, a research and development company, engages in the development of drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.
View company